Cite
HARVARD Citation
Keystone, E. et al. (2015). Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. Annals of the rheumatic diseases. 74 (2), pp. 333-340. [Online].